75116 A pooled analysis of the hemostatic safety profile of remibrutinib over 24 weeks in patients with chronic spontaneous urticaria from the REMIX-1 and REMIX-2 phase 3 studies

Journal of the American Academy of Dermatology 2026

View at publisher
Authors: Mark Lebwohl, Sarbjit Saini, Michihiro Hide, F. Bérard, Linfeng Li, Elodie Incera, Hichem Zouater, Karine Lheritier, Artem Zharkov, Knut Brockow
DOI: 10.1016/j.jaad.2026.04.099
Cited by: 1

Fields of Study & Subjects

Urticaria and Related Conditions Autoimmune Bullous Skin Diseases Hemophilia Treatment and Research

Publication details

Journal / source
Journal of the American Academy of Dermatology
Publisher
Elsevier BV
Volume
95
Issue
1
Pages
AB21–AB21
Publication date
1 July 2026
Language
EN